Gabriel S Macedo

List of Publications by Year
in descending order

25 papers	794 citations	840776 11 h-index	713466 21 g-index
25 all docs	25 docs citations	25 times ranked	1768 citing authors

#	Article	IF	Citations
1	Massively Parallel Sequencing-Based Clonality Analysis of Synchronous Endometrioid Endometrial and Ovarian Carcinomas. Journal of the National Cancer Institute, 2015, 108, djv427.	6.3	164
2	The Genomic Landscape of Male Breast Cancers. Clinical Cancer Research, 2016, 22, 4045-4056.	7.0	119
3	Massively parallel sequencing of phyllodes tumours of the breast reveals actionable mutations, and <scp>TERT</scp> promoter hotspot mutations and TERT gene amplification as likely drivers of progression. Journal of Pathology, 2016, 238, 508-518.	4.5	102
4	Uterine adenosarcomas are mesenchymal neoplasms. Journal of Pathology, 2016, 238, 381-388.	4.5	94
5	miRNA-21 and miRNA-34a Are Potential Minimally Invasive Biomarkers for the Diagnosis of Pancreatic Ductal Adenocarcinoma. Pancreas, 2016, 45, 84-92.	1.1	56
6	Polymorphisms of the UCP2 gene are associated with proliferative diabetic retinopathy in patients with diabetes mellitus. Clinical Endocrinology, 2010, 72, 612-619.	2.4	51
7	Are acinic cell carcinomas of the breast and salivary glands distinct diseases?. Histopathology, 2015, 67, 529-537.	2.9	37
8	Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases. Oncotarget, 2018, 9, 20617-20630.	1.8	36
9	Increased Oxidative Damage in Carriers of the Germline TP53 p.R337H Mutation. PLoS ONE, 2012, 7, e47010.	2.5	21
10	Rare germline variant (rs78378222) in the TP53 3' UTR: Evidence for a new mechanism of cancer predisposition in Li-Fraumeni syndrome. Cancer Genetics, 2016, 209, 97-106.	0.4	19
11	Reviewing the characteristics of BRCA and PALB2-related cancers in the precision medicine era. Genetics and Molecular Biology, 2019, 42, 215-231.	1.3	14
12	Genomic characterization of small cell carcinomas of the uterine cervix. Molecular Oncology, 2022, 16, 833-845.	4.6	14
13	Analysis of Predictive Biomarkers in Patients With Lung Adenocarcinoma From Southern Brazil Reveals a Distinct Profile From Other Regions of the Country. Journal of Global Oncology, 2019, 5, 1-9.	0.5	13
14	p53 signaling pathway polymorphisms, cancer risk and tumor phenotype in TP53 R337H mutation carriers. Familial Cancer, 2018, 17, 269-274.	1.9	11
15	The role of ESCO2, SALL4 and TBX5 genes in the susceptibility to thalidomide teratogenesis. Scientific Reports, 2019, 9, 11413.	3.3	11
16	Skin pigmentation polymorphisms associated with increased risk of melanoma in a case-control sample from southern Brazil. BMC Cancer, 2020, 20, 1069.	2.6	9
17	Comparison of multiple genotyping methods for the identification of the cancer predisposing founder mutation p.R337H in TP53. Genetics and Molecular Biology, 2016, 39, 203-209.	1.3	8
18	MIR605 rs2043556 is associated with the occurrence of multiple primary tumors in TP53 p.(Arg337His) mutation carriers. Cancer Genetics, 2020, 240, 54-58.	0.4	5

#	Article	IF	Citations
19	Clinical and molecular characterization of patients fulfilling Chompret criteria for Li-Fraumeni syndrome in Southern Brazil. PLoS ONE, 2021, 16, e0251639.	2.5	4
20	Genetic analysis of a morphologically heterogeneous ovarian endometrioid carcinoma. Histopathology, 2017, 71, 480-487.	2.9	2
21	Prevalence of the Brazilian TP53 Founder c.1010G>A (p.Arg337His) in Lung Adenocarcinoma: Is Genotyping Warranted in All Brazilian Patients?. Frontiers in Genetics, 2021, 12, 606537.	2.3	2
22	Abstract 100: The landscape of somatic genetic alterations in BRCA1 and BRCA2 breast cancers. , 2016, , .		1
23	Abstract 3379: Massively parallel sequencing analysis of breast adenomyoepitheliomas reveals the heterogeneity of the disease and identifies a subset driven byHRAShotspot mutations. , 2017, , .		1
24	Abstract 804: Energetic metabolism and DNA damage response in fibroblasts from Li-Fraumeni syndrome patients: new insights into the molecular mechanisms of the disease. , 2015, , .		0
25	A novel DMD intronic alteration: a potentially disease-causing variant of an intermediate muscular dystrophy phenotype. Acta Myologica, 2021, 40, 93-100.	1.5	0